NICOLE MICHAEL: Open Payments
NPI 1396562146 · REISTERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$465 in 23 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $61 · 2025 $465
Food & beverage: $465
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $54 |
| Novo Nordisk Inc | 2 | $51 |
| AstraZeneca Pharmaceuticals LP | 2 | $49 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $36 |
| Braeburn Inc. | 1 | $35 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Astellas Pharma US Inc | 2 | $33 |
| Indivior Inc. | 1 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $28 |
| AERIN MEDICAL INC. | 1 | $25 |
Products named: QULIPTA, JARDIANCE, BRIXADI, Auvelity, Veozah, SUBLOCADE, FARXIGA, CAPLYTA.
Industry payments across MD — which companies pay providers there.
